Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 2:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Diuretic Therapy Clear all
Recruiting Phase 2 Interventional

Ertugliflozin in Chronic Heart Failure

NCT04438213
View directory record Official record
Conditions
Heart Failure
Interventions
Ertugliflozin, Metolazone, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Determining Optimal Dose and Duration of Diuretic Treatment in People With Acute Heart Failure (The DOSE-AHF Study)

NCT00577135
View directory record Official record
Conditions
Heart Failure
Interventions
Furosemide-Q12 hour bolus, Furosemide-Continuous Infusion, Furosemide-Low Intensification, Furosemide-High Intensification
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Sep 26, 2026, 2:56 PM EDT
Terminated No phase listed Observational

Compensatory Reserve Index (CRI) for Management of COVID-19

NCT04457817
View directory record Official record
Conditions
COVID
Interventions
CRI
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Not applicable Interventional

Evaluation of Blood Volume Analysis- Guided Management of Decompensated Heart Failure

NCT04855097
View directory record Official record
Conditions
Acute Decompensated Heart Failure
Interventions
BVA-100
Diagnostic Test
Lead sponsor
Daxor Corporation
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Sep 26, 2026, 2:56 PM EDT
Terminated Phase 3 Interventional Results available

Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure

NCT00608140
View directory record Official record
Conditions
Mitral Valve Insufficiency, Heart Failure
Interventions
Surgical mitral valvuloplasty with placement of annular ring (SMVR), Optimal medical therapy (OMT)
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
Atlanta, Georgia • Boston, Massachusetts • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2018 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 3 Interventional Results available

Furoscix Real-World Evaluation for Decreasing Hospital Admissions in Heart Failure

NCT03458325
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix Infusor
Combination Product
Lead sponsor
scPharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Sylmar, California • Bridgeport, Connecticut • Tampa, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2023 · Synced Sep 26, 2026, 2:56 PM EDT
Terminated Not applicable Interventional

Syntrillo Telehealth Stroke Risk Reduction Study

NCT07124728
View directory record Official record
Conditions
Hypertension, Hypertension (HTN), Stroke Prevention, Cardiovascular Risk Factor
Interventions
Technology-enabled Telehealth Care Plan, Blood Pressure Monitoring Device, Tenovi Smart Pillbox, Wearable Activity Trackers (Fitbit or Apple Watch), Healthie EHR, Secure Messaging Platforms (TigerConnect, Weave, AirCall), Antihypertensive Medication Management, Statin Medication Management, Antiplatelet or Anticoagulant Therapy, Laboratory Blood Test Collection
Behavioral · Device · Other + 2 more
Lead sponsor
Syntrillo, Inc
Other
Eligibility
30 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 26, 2026, 2:56 PM EDT
Terminated Not applicable Interventional Results available

Handheld Ultrasound Evaluation of the Inferior Vena Cava to Guide Heart Failure Treatment

NCT01962688
View directory record Official record
Conditions
Heart Failure
Interventions
Handheld ultrasound, Sham ultrasound
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 3 Interventional

DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension

NCT00389779
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan, Guanfacine, Darusentan Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
849 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
87
States / cities
Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 70 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 2 Interventional Results available

Furoscix in Heart Failure Patients With Diuretic Resistance

NCT05528588
View directory record Official record
Conditions
Heart Failure
Interventions
Furoscix, Diuretic Therapy
Combination Product · Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2025 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Early Phase 1 Interventional

N-of-1 Trials for Blood Pressure Medications in Adults

NCT02744456
View directory record Official record
Conditions
Hypertension, High Blood Pressure
Interventions
Losartan, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Columbia University
Other
Eligibility
21 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Results available

Effects of Thiazide Diuretics on Sympathetic Nervous System in Hypertension

NCT00353652
View directory record Official record
Conditions
Hypertension
Interventions
Study#1: chlorthalidone (CTD), titrated dose, Study #1: spironolactone (SP), titrated dose, Study# 2 chlorthalidone (CTD), fixed dose, Study# 2 spironolactone (SP), fixed dose, Study# 2 irbsesartan (IR), fixed dose
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
2
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 5, 2019 · Synced Sep 26, 2026, 2:56 PM EDT
Terminated Phase 2 Interventional Results available

Subcutaneous Furosemide in Acute Decompensated Heart Failure: The SUBQ-HF Study

NCT03170219
View directory record Official record
Conditions
Acute Heart Failure, Decompensated Heart Failure
Interventions
subcutaneous furosemide and sc2wear device
Combination Product
Lead sponsor
Adrian Hernandez
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
16
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Sep 26, 2026, 2:56 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

NCT06975111
View directory record Official record
Conditions
Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
Interventions
Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 26, 2026, 2:56 PM EDT
Terminated Phase 3 Interventional Results available

Surgical Idiopathic Intracranial Hypertension Treatment Trial

NCT03501966
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Optic Nerve Sheath Fenestration, Ventriculoperitoneal CSF Shunting
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 63 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
33
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Not applicable Interventional

Renin Profiling in Selection of Initial Antihypertensive Drug

NCT00834600
View directory record Official record
Conditions
Hypertension
Interventions
olmesartan, hydrochlorothiazide, amlodipine, hydrochlorothiazide (HCTZ) or olmesartan
Drug
Lead sponsor
The Louis & Rachel Rudin Foundation
Other
Eligibility
40 Years to 85 Years
Enrollment
185 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
5
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 18, 2012 · Synced Sep 26, 2026, 2:56 PM EDT
Recruiting Not applicable Interventional

Preventing Cognitive Decline by Reducing BP Target Trial

NCT05106036
View directory record Official record
Conditions
Cognitive Decline, Blood Pressure, Hypertension
Interventions
Clinical Support Decision Tool
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
70 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Not applicable Interventional

Treatment of Tricuspid Valve Regurgitation in Patients Undergoing Left Ventricular Assist Device Implantation Study

NCT03775759
View directory record Official record
Conditions
Tricuspid Valve Insufficiency, Right Heart Failure, Heart Failure
Interventions
Tricuspid valve repair or replacement, Medical management of tricuspid regurgitation
Procedure · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Sep 26, 2026, 2:56 PM EDT
Terminated Not applicable Interventional

Recovery After Dialysis-Requiring Acute Kidney Injury

NCT03305549
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Conservative dialysis strategy, TIW dialysis strategy
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 18, 2025 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 4 Interventional

Trial Assessing the Effect of Preoperative Furosemide on Intraoperative Blood Pressure

NCT00115726
View directory record Official record
Conditions
Hypertension, Hypotension, Edema, Congestive Heart Failure
Interventions
furosemide, placebo
Drug
Lead sponsor
University of Calgary
Other
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2008 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Results available

Extracorporeal Ultrafiltration (UF) vs. Usual and Customary Care for Patients With Severe Heart Failure (HF)

NCT00288587
View directory record Official record
Conditions
Heart Failure, CHF
Interventions
IV loop diuretic, NxStage System One
Drug · Device
Lead sponsor
NxStage Medical
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 18, 2012 · Synced Sep 26, 2026, 2:56 PM EDT
Completed Phase 4 Interventional Results available

Tolvaptan For Worsening Outpatient Heart Failure: Role of Copeptin In Identifying Responders

NCT02476409
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
tolvaptan, Placebo
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 26, 2026, 2:56 PM EDT
Recruiting Not applicable Interventional

Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants

NCT05547165
View directory record Official record
Conditions
Ductus Arteriosus, Patent
Interventions
Percutaneous Patent Ductus Arteriosus Closure (PPC), Responsive Management Intervention, Echocardiogram, cardiac
Device · Combination Product · Diagnostic Test
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
7 Days to 32 Days
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
24
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2025 · Synced Sep 26, 2026, 2:56 PM EDT
Completed No phase listed Observational

Developing Hyperpolarized 129Xe MRI Biomarkers for Evaluation of Pulmonary Arterial Hypertension

NCT05339386
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 26, 2026, 2:56 PM EDT